ArticleThe Laryngoscope2026
Longitudinal SNOT-22 Symptom Changes With Sublingual Immunotherapy (SLIT).
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDespite widespread use of nasal corticosteroids and oral antihistamines, many patients with allergic rhinitis (AR) have persistent nasal congestion/obstruction and rhinorrhea with associated sleep disturbance and daytime fatigue. Sublingual immunotherapy (SLIT) is associated with reducing symptom burden and medication use. This study aims to evaluate time to clinical benefit and magnitude of first-year benefit after SLIT initiation.
methodsAdult AR patients confirmed by skin or IgE testing who initiated allergen-directed SLIT were included. Sinonasal Outcome Test-22 (SNOT-22) and Rhinitis Control Assessment Test (RCAT) surveys were recorded at baseline, 1-6, and 6-12 months after SLIT. Longitudinal changes were assessed using repeated measures analysis of variance and minimal clinically important difference (MCID) thresholds. Exploratory analysis at 3 months was performed for a subset of patients.
resultsA total of 43 SLIT patients (mean age 42.1 ± 12.0 years; 40% female) were included and demonstrated significant reductions in total SNOT-22 scores at 1-6 months (-12.1 points; -35%) and 6-12 months (-12.5 points; -36%) (p < 0.01 from baseline). Nasal, sleep, and function SNOT-22 subscores each improved significantly from baseline, whereas the ear/facial subscore did not. MCID for total SNOT-22 was achieved by 54.3% of patients at 1-6 months. RCAT scores improved significantly at 1-6 months and 6-12 months. The proportion of patients with normal SNOT-22 score (≤ 8) increased from 4.7% at baseline to 24.1% at 6-12 months.
conclusionsSLIT was associated with symptom improvement within the first 6 months of therapy based on SNOT-22 and RCAT scores. Symptom score improvements persisted to 12 months, and findings support evidence of early nasal, sleep, and function symptom alleviation with SLIT. LEVEL OF EVIDENCE: 4:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.